



Conference on ‘Getting energy balance right’ Symposium 1: Regulation of energy balance and whole body metabolism

The relationships between sarcopenic skeletal muscle loss during ageing and macronutrient metabolism, obesity and onset of diabetes

Ailsa A. Welch*, Richard P. G. Hayhoe and Donnie Cameron
Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK

Skeletal muscle is integral to the metabolism and utilisation of macronutrients; however, substantial muscle loss and morphological changes occur with ageing. These are associated with loss of muscle function and accelerate rapidly from the age of 60 years, leading to the conditions of sarcopenia and frailty. As the relationship between muscle ageing and macronutrient metabolism and utilisation has seen limited research to date, this review focuses on the interactions between skeletal muscle changes during ageing, metabolism and utilisation of fat, carbohydrates and overall energy expenditure.

Skeletal muscle contributes less to resting energy expenditure during ageing, potentially contributing to onset of obesity from middle age. Age-related changes to skeletal muscle lead to glucose dysregulation, with consequent reduction in glycaemic control, increased insulin resistance and ultimately onset of type-2 diabetes. Recent studies indicate that high total fat and SFA intake are detrimental to skeletal muscle, while higher intakes of PUFA are protective. Age-associated changes in skeletal muscle may also reduce total fatty acid utilisation.

In conclusion, further research is needed to understand the relationships between macronutrient metabolism and utilisation and age-related changes to skeletal muscle. No dietary recommendations exist specifically for skeletal muscle health during ageing, but we advise individuals to follow healthy eating guidelines, by consuming sufficient protein, fruit and vegetables, and limited SFA and to maintain physically active lifestyles. Clinicians responsible for managing type-2 diabetes need to be aware of growing evidence relating age-related skeletal muscle changes to diabetes onset and progression.

Skeletal muscle: Sarcopenia: Macronutrients: Dietary fat: Obesity: Diabetes

Maintaining skeletal muscle mass (SMM) and function is important for health, but loss of both occurs as a natural consequence of ageing. This loss starts from mid-life, as early as age 40 years, and progresses more rapidly over the age of 60 years^(1–4). Sarcopenia, the presence of low skeletal mass and function, is the result of the gradual decline with age in muscle strength as well as mass. The most recent definition of sarcopenia focuses on functional aspects whilst acknowledging that the role of SMM requires further research^(5–7). Sarcopenic obesity is the presence of sarcopenia, as low lean mass, in combination

with obesity; this condition is also increasingly prevalent in older populations^(1,8–11). Moreover, sarcopenia and age-related skeletal muscle loss are key contributors to frailty. Research and clinical interest for sarcopenia have largely focused on the functional consequences of the loss of muscle with age, such as reduced mobility and increased falls and fractures. There has been less focus on the metabolic and homeostatic importance of skeletal muscle and the consequences of this skeletal muscle loss on nutritional biochemistry and metabolism and utilisation of macronutrients^(1,12–17).

Abbreviations: FFM, fat free mass; ROS, reactive oxygen species; REE, resting energy expenditure; SMM, skeletal muscle mass; TEE, total energy expenditure.

*Corresponding author: Ailsa A. Welch, email a.welch@uea.ac.uk

Skeletal muscle is integral to the metabolism and utilisation of the macronutrients protein, fat and carbohydrate, as well as overall energy metabolism. However, the age-related loss of SMM, changes in skeletal muscle morphology and the consequent effects and interactions on metabolism of macronutrients are much less appreciated⁽¹²⁾.

The prevalence of sarcopenia is high in residential care and in the community (14–33 and 29 %, respectively), and the number of individuals with sarcopenia is predicted to nearly double in the next 30 years^(6,18). Sarcopenia is also a component of frailty, which has a prevalence of 25 % in those over the age of 80 years⁽¹⁹⁾. The age-related losses and changes to morphology of skeletal muscle also have consequences for carbohydrate metabolism, as this is used by skeletal muscle as glucose, released by digestion of carbohydrate. This has implications for the onset of insulin resistance and type-2 diabetes^(1,2,13,14,20–23). Loss of skeletal muscle also has implications for energy expenditure and concomitant risk of onset of obesity. Given the prevalence of sarcopenia, frailty, obesity and type-2 diabetes in adulthood in Western populations, the overall costs and burden to health and social care are vast^(20,21,24). These costs and the burden to society will also increase in the future, given the predicted increase in the prevalence of sarcopenia and its associated conditions, and the increasing age profile of Western populations.

As the nutritional and metabolic consequences of the loss of skeletal muscle, and changes to skeletal muscle quality, have received less attention than the functional consequences, these aspects form the focus of this review⁽¹²⁾. This paper provides an overview of the metabolic consequences of age-related changes and loss of SMM on the metabolism of macronutrients, particularly fat and fatty acids, and carbohydrate, and effects on overall energy expenditure during middle and older age. Morphological changes to fibre type and muscle composition in relation to macronutrient metabolism and utilisation are highlighted⁽²⁵⁾. The effects of morphological changes and losses of SMM on resting energy expenditure (REE), and concomitant risk of onset of obesity, as well as on insulin resistance, control of blood glucose, and the contribution to the onset of type-2 diabetes are described^(1,2,13,14,20,21). The relationships between the effects of diabetes on further changes and loss of skeletal muscle, as well as the potential impact of certain fatty acids on quantity and morphology of skeletal muscle, are also covered, and are illustrated in Fig. 1.

The effects of ageing on skeletal muscle mass and morphology

Measuring skeletal muscle and terminology

A number of methods are available for measuring total body composition *in vivo*, ranging from bioelectrical impedance to dual-energy X-ray absorptiometry. Measures of SMM are typically calculated from these methods. In ‘reference man’ (a traditional term, arising from early research in this area, that describes the typical

body composition of adult males of an average body weight) total body mass consists of about 19 % fat mass and 81 % fat free mass (FFM), 91 % of which is lean soft tissue mass, with the remainder consisting of bone^(26–32). However, in women the proportion of fat mass in the body is, in the main, greater than in men and so is associated with a correspondingly lower proportion of FFM; see also section ‘Loss of skeletal muscle mass’ for further details. Development of three- and four-compartment methods for measuring SMM in populations is relatively recent, and much of the literature relating to sarcopenia and skeletal muscle refers to FFM, which has been considered a suitable measure of SMM, given that contributions from bone are small^(3,26–30,33). Appendicular lean mass or appendicular skeletal muscle mass is the sum of lean tissue in the arms and legs^(26–30).

Scaling for body size

Since FFM increases with greater body weight and height, studies in human subjects are scaled for body size^(29,34–36). Scaling can be by height, height², as a percentage of total body weight or by BMI.

Loss of skeletal muscle mass

Skeletal muscle, measured as FFM, accounts for about 70–80 % of body weight in men and 65–75 % in women of middle and early older age⁽³⁷⁾. Losses of SMM are gradual and progressive, ranging from 0.5 to 1 % per year, starting around middle age, with rates increasing over the age of 60 years^(1–3). Men experience greater rates of loss during older age, although their FFM, as a proportion of body size, is greater than in women at all life stages.

Muscle morphology changes during ageing and links to fat, carbohydrate and energy metabolism

Skeletal muscle is composed of three distinct types of muscle fibre, categorised by their energy metabolism and their myosin structures: slow-twitch, oxidative, type-I fibres; fast-twitch, oxidative-glycolytic, type-IIa fibres and fast-twitch, glycolytic, type-IIb fibres. Each category of fibre also shows different capacities for fatty acid utilisation, with type-I fibres contributing more to fatty acid oxidation and being more insulin-sensitive than type-IIb fibres⁽³⁸⁾. Human muscle shows multiple fibre types within a single muscle group, with different proportions of fibre types in each muscle; for example, the soleus muscle in the calf has mostly type-I fibres, while the vastus lateralis muscle in the thigh is largely type II⁽³⁹⁾. These proportions are flexible, however, and muscle fibres can remodel their phenotypes to adapt to different circumstances, including ageing⁽⁴⁰⁾.

Ageing is associated with a conversion of muscle fibres to slow-twitch, oxidative, type-I fibres, and type-II fibres are seen to atrophy and shrink in diameter, while type-I fibres are relatively unaffected⁽⁴¹⁾. This may relate to damage, and ultimately breakage, experienced by muscle fibres during the ageing process⁽⁴²⁾. Further, the total




Fig. 1. Overview of the relationships between age-related changes to skeletal muscle macronutrient metabolism and utilisation, and onset of type-2 diabetes and obesity. Circulating glucose arises from metabolism of carbohydrate. IR, insulin resistance.

number of muscle fibres in skeletal muscle decreases with age⁽⁴³⁾, along with the cross-sectional area of the muscle, which has been shown to decrease by 25–35 % in older men and women^(44,45). See Wilkinson, Piasecki and Atherton for a review of muscle fibre loss and atrophy with ageing⁽⁴⁶⁾. Measures of cross-sectional area underestimate losses in muscle contractile tissue, as muscle ageing is also accompanied by infiltration of fatty and fibrotic tissue⁽⁴⁷⁾, which contributes to the disparity between mass and strength losses in sarcopenia. Fatty infiltration (myosteatosis) is related to the higher content of saturated ceramide and diacylglycerol fatty acids in older age⁽⁴⁸⁾.

Mitochondrial effects during ageing and interaction with macronutrient metabolism

Mitochondria are also important in the context of ageing. In the cell, mitochondria are essential to metabolism as they use oxidative phosphorylation to produce a ready supply of ATP, a fundamental energy unit for cellular processes. Mitochondria in skeletal muscle form complex, anisotropic networks⁽⁴⁹⁾ that supply energy to fuel muscle contraction. There are two distinct subpopulations of mitochondria; one directly beneath the sarcolemma, and the other between myofibrils⁽⁵⁰⁾. Slow-twitch oxidative muscle fibres contain many more mitochondria than fast-twitch glycolytic fibres, and are more resistant to fatigue due to the large amount of ATP generated by their mitochondria. The oxidative phosphorylation efficiency of mitochondria, their capacity to produce ATP, has been shown to decline with age⁽⁵¹⁾, and is also influenced by insulin resistance, as discussed later in this review. Mitochondria also contribute to the ageing

process: dysfunctional mitochondria accumulate with age, particularly in skeletal muscle⁽⁵²⁾, and they ultimately become senescent⁽⁵³⁾, losing the ability to proliferate. Dysfunctional mitochondria generate reactive oxygen species (ROS), and the damage associated with these is central to some pathologies, as well as ageing^(54–56); these dysfunctional mitochondria produce a vicious cycle of damage and deterioration in ageing muscle.

The ligand binding nuclear receptors found in skeletal muscle are transcription factors involved in metabolic control within skeletal muscle; see Baskin for an elegant review⁽⁵⁷⁾. PPAR are critical regulators of the metabolic genes in striated muscle⁽⁵⁸⁾, with PPAR α being involved in transcription of the genes required for fatty acid uptake or oxidation. PPAR α activation induces fatty acid utilisation in skeletal muscle⁽⁵⁹⁾. Also PPAR γ coactivator 1 α , along with PPAR α , coordinates metabolic regulation within skeletal muscle, further regulating the GLUT4, cAMP response element binding protein and nuclear respiratory factors to mediate transcription of genes involved in fatty acid and glucose metabolism⁽⁵⁷⁾.

In summary, the total number and diameter of skeletal muscle fibres decreases with age, fibre type shifts to slow-twitch type-I fibres that are more insulin-resistant and do not utilise glucose. Mitochondria become dysfunctional, or senescent, and generate ROS that further damage muscle. Further age-related changes in skeletal muscle morphology include infiltration of non-contractile material in muscle tissue, denervation, a reduction in the number of satellite cells, and a weakening of the connections between muscle and tendons. All of these have consequences for the functional capacity of skeletal muscle, as well as its ability to regenerate when damaged. The loss of SMM and morphological changes associated with ageing have the potential to impact directly on oxidation and utilisation of fatty acids as well as glucose utilisation and energy metabolism, see [Table 1](#).

Protein metabolism and muscle

Skeletal muscle is the main reservoir of amino acids in the body; these are stored as protein, and are required for the maintenance of protein synthesis within skeletal muscle^(2,13,14,60–63). This store is activated during deficits of energy intake, and during periods of increased demand, to satisfy the energy requirements of the body through catabolism of protein and gluconeogenesis^(2,13,14,60–63). Thus, the loss of SMM with age diminishes reserves of amino acids, stored as protein with the body. Maintaining the balance between protein synthesis, anabolism, and protein breakdown, catabolism, is also crucial to conservation of skeletal muscle during ageing^(2,12,13,61,64). However, several mechanisms of ageing disrupt this balance, leading to catabolism. Such mechanisms include ROS, circulation of inflammatory cytokines, and the insulin resistance that leads to type-2 diabetes^(22,65). Therefore, the onset of insulin resistance and type-2 diabetes disrupts protein synthesis,

Table 1. Age-related changes to morphology and quantity of skeletal muscle and interactions with macronutrient metabolism

Fibre type		Ageing effects	Nutrients
Type I (slow)	–Oxidative >Mitochondria v. type II >Insulin sensitivity v. type II	↓Number ↑Proportion	Glucose (↓ with age) Fatty acids (↓ with age)
Type II (fast)	–Oxidative-Glycolytic (IIa) –Glycolytic (IIb)	↓Number ↓Proportion Atrophy	Glucose (↓ with age) Fatty acids (↓ with age)

contributing to changes in SMM and morphology, as described later.

As the topic of protein in relation to skeletal muscle is covered in full elsewhere, newer aspects of research relating to skeletal muscle and its importance to metabolism of carbohydrate, fat and energy metabolism are covered in the following sections.

The effects of ageing of skeletal muscle on energy expenditure and risk of obesity

Components of energy expenditure and balance between energy intake and energy expenditure

Total daily energy expenditure (TEE) comprises three main components: (1) REE, also referred to as RMR or BMR; (2) the thermic effect of food and (3) the energy expenditure associated with physical activity. See Fig. 2 for an illustration of these. In adults, REE accounts for 60–70 % of total energy requirements in healthy adults^(32,66–69). The proportion of REE attributable to organ mass ranges from about 5 to 10 %^(32,68,69). FFM is the main predictor of REE, which is determined by the metabolism of macronutrients protein, carbohydrate, fat and alcohol. The contribution of the thermic effect of food to TEE is estimated at about 10 % of TEE. The contribution of habitual and discretionary physical activity to TEE is variable, ranging from about 15 % in very sedentary people to about 50 % in those who are very physically active. TEE reduces during ageing, partly due to reductions in habitual and discretionary physical activity but also due to the loss of metabolically active FFM, which consists of both skeletal tissue and that found in the internal organs.

A balance must be maintained between energy expenditure and energy intake, derived from macronutrients and alcohol, in order to maintain a steady body weight, as described in Fig. 2. Body weight increases when excess energy intake is consumed compared with total energy expended.

Metabolic rate decreases with age in relation to loss of skeletal muscle mass and in clinical conditions of ageing

In the early 20th century, age-related reductions in BMR were observed, with Lewis finding that ‘0.664 calories per hour per square meter per hour’ were lost per decade of age in men⁽⁷⁰⁾. That this was attributable to loss of SMM with age has been elaborated with further findings during this century in both men and women. Ravussin’s study in

1986 identified the key determinants of 24-h energy expenditure in man, finding that FFM explained 81 % of the variance in energy expenditure in an obese population⁽⁷¹⁾. Furthermore, even after accounting for physical and spontaneous activity and the thermic effect of food, FFM remained the most important determinant of energy expenditure⁽⁷¹⁾. Subsequent studies found that RMR was lower in older than in younger men, and this was attributable to the lower proportion of FFM in older men⁽⁷²⁾. Zurio and colleagues also found that differences in resting muscle metabolism partly accounted for the variance in metabolic rate amongst individuals of normal body weight⁽⁷³⁾. Overall, findings were summarised by Weinsier and colleagues in 1992⁽⁷⁴⁾.

Recent research also indicates that FFM is a key predictor of TEE even in highly active younger people⁽⁷⁵⁾. This study measured energy expenditure using the doubly labelled water technique in military personnel engaged in intensive operations. Whilst physical activity was a key predictor of energy expenditure in this group (r 0.9, $P < 0.05$) the association of energy expenditure with FFM was greater than that with total body mass (r 0.32, $P < 0.05$; and r 0.28, $P < 0.05$, respectively) even in this population with a high physical activity.

Sex-specific differences in the relationship between total FFM and REE have been explored further⁽⁶⁷⁾. In men and women aged 18–79 years, women experienced an earlier decline in SMM than men, starting at age 29 years v. 39 years in men. However, SMM, adjusted for fat mass, remained the main determinant of REE in both men and women, with R^2 0.67 in women and R^2 0.66 in men⁽⁶⁷⁾. More recent work also suggests that the proportion of FFM impacts on, and partially determines, energy intake and expenditure, via its mediating effect on RMR⁽⁷⁶⁾.

During ageing, the contribution of FFM to REE declines in parallel with the age-related decline in FFM, explaining 59.7 % of the decrease in REE. This indicates that the importance of FFM to REE increases with age⁽⁶⁷⁾. This is particularly important in underweight older people with low FFM^(74,77), and the situation is exacerbated in nonagenarians⁽⁷⁸⁾. Indeed, two recent studies found that decreased BMR is an objective marker for sarcopenia and frailty in older adults^(78,79). Thus, in elderly people who are underweight and have low physical activity, REE represents the greatest part of TEE^(74,77).

Overall, the contribution of FFM to TEE increases with age as the contribution of physical activity declines.




Fig. 2. Components of energy expenditure, energy intake and the concept of energy balance in older adults. Energy is released from metabolism of the macronutrients protein, carbohydrate and fat as well as alcohol. Energy expenditure comprises: resting energy expenditure (REE) or BMR, daily activities and discretionary physical activity and the thermic effect of digestion of food. Greater intake of total energy than total energy expenditure results in gain in body weight.

The effects of age-related skeletal muscle loss on metabolic rate and the onset of obesity

In middle and early-older-age the age-related decline in FFM and SMM may have implications for the onset of obesity. Obesity arises from the imbalance of energy intake and expenditure, and so the gradual loss of muscle mass with age has potential consequences for habitual energy expenditure and the energy imbalance that leads to the onset of obesity⁽²⁾. Discretionary and habitual physical activity also declines during ageing, contributing to overall reductions in energy expenditure. Two studies found that skeletal muscle fibre-type proportion is related to obesity. The first found that obese men had a higher proportion of fast-twitch, type-II fibres in the *vastus lateralis* muscle⁽⁸⁰⁾. The second confirmed these findings in obese women and found that the effectiveness of a weight-loss intervention was positively related to the percentage of slow-twitch, type-I fibres, which contain a greater proportion of mitochondria than do fast-twitch fibres⁽⁸¹⁾, as discussed in the section 'The effects of ageing on skeletal muscle mass and morphology'.

Robert Wolfe, in his important paper, calculated that every 10 kg of lean mass that is lost with age translates to a decrease in energy expenditure of about 418 kJ/d, assuming a constant rate of turnover⁽²⁾. This is equivalent to an accumulation of about 4.7 kg fat mass per year, assuming 1 kg fat store represents 32 217 kJ. Clearly, this difference in energy expenditure would disproportionately affect older individuals, who tend to have lower levels of physical activity and thus greater potential to develop obesity, as well as sarcopenic obesity.

In summary, evidence is now clear that skeletal muscle contributes a lower proportion of REE to TEE during ageing, potentially contributing to onset of obesity from middle-age onwards.

Effects of ageing of skeletal muscle on glucose metabolism, insulin resistance and risk of type-2 diabetes

Age-related changes in skeletal muscle, in terms of loss of quantity and morphology, impact on glucose metabolism, blood glucose control, insulin resistance and onset of type-2 diabetes, as shown in Fig. 3 with the mechanisms involved as follows^(1,2,20,21,23,82-84). Glucose, which arises from digestion of carbohydrate, is released into the bloodstream. Skeletal muscle is the organ responsible for the greatest insulin-stimulated glucose disposal in the body, accounting for about 75 % of glucose uptake⁽⁸⁵⁾. When skeletal muscle contractile tissue is lost during ageing, this leads to lower glucose uptake from the circulation. This and the increase in fat and ceramide infiltration is a contributory cause of insulin resistance, which is itself associated with reduced skeletal muscle mitochondrial function in older adults⁽⁸⁶⁾; indeed, mitochondrial dysfunction and insulin resistance appear to reinforce one another in a feedback loop⁽⁸⁷⁾. See a review by Affourtit for more information on the links between mitochondrial function and insulin resistance⁽⁸⁸⁾. These links highlight an association between the loss of SMM and mitochondrial function with age with the onset of type-2 diabetes. Therefore, age-related changes in skeletal muscle have implications for the onset and treatment of type-2 diabetes^(20,82-84,89).

Low skeletal muscle mass, sarcopenia and dynapenia are associated with or predict incidence of type-2 diabetes

A number of cross-sectional studies have demonstrated that low SMM is associated with insulin resistance or type-2 diabetes^(20,90-96). Existing sarcopenia or dynapenia is also a risk factor for onset of diabetes, as is low SMM⁽⁹⁷⁻⁹⁹⁾. An increased hazard risk of 2.05 (95% CI 1.73, 2.43) was associated with onset of type-2 diabetes




Fig. 3. Relationships between age-related changes to morphology and quantity of skeletal muscle, glucose metabolism, insulin resistance and type-2 diabetes. The age-related changes in skeletal muscle lead to reduction in glycaemic control, increased insulin resistance and onset of type-2 diabetes. That onset of the poor glycaemic control also accelerates skeletal muscle loss and morphological changes leading to a vicious cycle of age-related muscle changes in those with type-2 diabetes.

over 9 years in those with the lowest muscle mass index (appendicular lean mass adjusted for weight), compared with the highest tertile of muscle mass index, who had double the risk⁽¹⁰⁰⁾. Moreover, this increased risk of type-2 diabetes was due to relatively small differences in muscle mass index at baseline of only 5.4 % between those at the greatest and least risk. Subsequently, maintenance of appendicular skeletal muscle mass was also found to be protective against the development of type-2 diabetes in men but not women, independent of obesity⁽¹⁰¹⁾. However, a further study contradicted this finding, as women with a higher SMM were at greater risk of incident type-2 diabetes⁽¹⁰²⁾.

Impact of type-2 diabetes on skeletal muscle

Evidence is building that the presence of type-2 diabetes in older people leads to significant loss of SMM over time^(100,103). One study found that accelerated loss of SMM occurred in middle-aged and older women with diabetes⁽¹⁰⁴⁾; this is due to a number of disease processes, including the poor glycaemic control that is often associated with the existence of mild metabolic acidosis^(95,105,106). That this is the case was confirmed in a study where treatment of diabetes with insulin attenuated the decline in muscle mass⁽¹⁰⁷⁾.

In summary, age-related changes to skeletal muscle lead to glucose dysregulation, with consequent reduction in glycaemic control, increased insulin resistance and ultimately onset of type-2 diabetes, as shown in Fig. 3^(20,82–84,89). These age-related changes in skeletal muscle also have implications for the progression of type-2 diabetes, with the onset of poor glycaemic control also accelerating skeletal muscle loss and the morphological changes that occur with age, leading to a vicious cycle of damage to muscle, as in Fig. 3.

Role of fat intake and metabolism on age-related muscle loss

Skeletal muscle is also central to the metabolism of dietary fat, with the fatty acids derived from fat being the main source of energy for resting and working muscle^(2,108,109). As discussed earlier, the ligand-binding nuclear receptor PPAR α , when bound to long-chain fatty acids, activates

transcription of genes involved in fatty acid uptake and oxidation, and robustly induces utilisation of fatty acids in muscle tissue⁽⁵⁷⁾. Likewise, PPAR β and PPAR γ are also involved in regulating fatty acid metabolism in skeletal muscle. Thus, reduction in SMM during ageing may also reduce the capacity for fatty acid metabolism. Also, recent but limited research in human and animal studies has identified the relevance of dietary fatty acid intake to skeletal muscle in ageing^(17,110).

Dietary fat intake varies significantly in terms of the total amount and the proportion of different fatty acids. Indeed, all sources of fat are mixtures of the different classes of fatty acids, including SFA, MUFA and PUFA. Considering the range of different sources of fat used in food manufacture and meal preparation, the profile of different fatty acid intakes for different individuals within and between populations can be highly variable⁽¹¹¹⁾.

It is important to consider both that dietary fat is integral to the muscle membrane (the sarcolemma) and that fatty acids act as the dominant substrate for the production of ATP during aerobic exercise^(108,109). Long-chain NEFA circulate in the blood, and protein transporters, including fatty acid binding protein in the plasma membrane, fatty acid translocase and the fatty acid transport protein, facilitate their transfer across the sarcolemma⁽¹¹²⁾. Moreover, the specific fatty acid profile of the diet is reflected in the fatty acid composition of the sarcolemma, although this may also be altered by other physiological processes including exercise stimulation of skeletal muscle^(113,114). The profile of fatty acids is also relevant since fatty acids have been shown to be oxidised in a specific order of preference, with oleic and unsaturated fatty acids oxidised in preference to SFA⁽¹¹⁵⁾.

In terms of the mechanisms behind these associations, some studies have shown that dietary fat intake can affect inflammatory status, which may have consequences for skeletal muscle. Previous observational studies have suggested that both the total fat intake and the proportion of different fatty acids may be relevant in the mechanisms leading to skeletal muscle loss and sarcopenia^(17,116). In particular, high total fat and SFA intakes may be detrimental to skeletal muscle health, and higher proportions of PUFA (total, *n*-3 PUFA, *n*-6 PUFA), MUFA and the PUFA:SFA ratio may be beneficial^(17,116). However, the




Fig. 4. Relationships between age-related changes to morphology and quantity of skeletal muscle and fatty acid metabolism. This figure summarises the relevance of fatty acids to skeletal muscle changes during ageing, including increased loss of muscle mass, increased ceramide and fat infiltration and reduced ATP production. High total fat intake may cause some skeletal muscle changes directly, but may also act via inflammatory pathways (also affected by high SFA: PUFA dietary ratios). Decreased fatty acid utilisation as a result of skeletal muscle changes may feedback so the process continues.

recent Scientific Advisory Committee on Nutrition report on SFA and health made no specific comments on the effects of SFA on skeletal muscle, due to a lack of research⁽¹¹⁷⁾. As discussed earlier, inflammation pathways are intricately involved in the processes of ageing and sarcopenia. High intakes of total fat and SFA are typically viewed as risk factors for inflammation, while *n*-3 PUFA are more recognised for their anti-inflammatory properties and potential for increasing protein synthesis^(17,116,118–120). However, despite this, a recent systematic review and meta-analysis of randomised controlled trials found little or no association of *n*-3, *n*-6 and total PUFA on skeletal muscle outcomes, largely due to insufficient evidence of high quality⁽¹⁶⁾.

One inflammatory mediator previously shown to be found in higher concentrations in older individuals is IL-6⁽¹²¹⁾. This molecule is produced in skeletal muscle and is known to affect both glucose and fatty acid metabolism in muscle⁽¹²²⁾. Indeed, it has been hypothesised that IL-6 is a key factor in insulin resistance, and thus increased concentrations in the elderly may have important metabolic consequences.

As described earlier with reference to insulin resistance, during ageing there is an increase in the lipid infiltration within skeletal muscle fibres (myosteatosis) and an associated reduction in the oxidative capacity of the muscle. This change in skeletal muscle composition is affected by dietary fat intake, as shown in animal work where significantly higher muscle lipid deposition was seen in mice fed on a high-fat diet *v.* those fed a control diet⁽¹²³⁾. This lipid deposition may lead to mitochondrial dysfunction, decreasing ATP production and increasing ROS production, and it may also result in insulin resistance. ROS can act as second messengers for TNF- α in skeletal muscle tissue and can result in NF- κ B activation, causing an increase in IL-6⁽¹²⁴⁾. The resulting increased inflammatory state may be of further detriment to normal skeletal muscle health. Observational study data have shown frail adults to have higher levels of intramuscular adipose tissue than non-frail individuals, and the quantity of intramuscular adipose tissue is significantly positively associated with IL-6 expression and protein within the muscle⁽¹²⁵⁾. It is not clear whether the predominant direction of the relationship is that an inflammatory environment in the muscle

exacerbates lipid infiltration, or conversely that an increase in inflammatory signalling molecules is a result of fat infiltration, but both may occur. Irrespective of this, the close proximity of fat to the muscle in the event of inflammatory cytokine release is likely to result in more profound effects on skeletal muscle dysfunction than of a more systemic increase in inflammatory load.

In summary, there is an important role for fatty acids in skeletal muscle health during ageing through mechanisms including fatty acid infiltration and enhanced inflammatory status, with consequences for metabolism and further adverse knock-on effects to SMM and function, see Fig. 4. While total fat intake is relevant, the balance between different fatty acids in the diet appears to be particularly important^(121,122).

Conclusions

Age-related changes in skeletal muscle in terms of quantity and morphology have important consequences for the metabolism and utilisation of macronutrients. Recent research indicates these age-related changes to skeletal muscle have the potential to impact directly on oxidation and utilisation of fatty acids as well as glucose utilisation and energy metabolism. Evidence is now clear that age-related changes to skeletal muscle contribute to lower REE during ageing, potentially playing a part in the onset of obesity from middle-age onwards. The effects of age-related changes in skeletal muscle that lead to glucose dysregulation, reduction in glycaemic control, increased insulin resistance and onset of type-2 diabetes are beginning to be recognised. That the onset of the poor glycaemic control also accelerates skeletal muscle loss and morphological changes leading to a vicious cycle of age-related muscle changes in those with type-2 diabetes is also important. There is also an important role for fatty acids in skeletal muscle health during ageing, from both total fat intake and the balance between different fatty acids in the diet, with metabolic consequences of fatty acid infiltration in muscle and altered inflammatory status causing negative effects on SMM and function. Further work is required to determine whether the role of fatty acids in skeletal muscle differs by sex and by age group.

*Practical public health messages for people of middle and older age*

There is a need to conserve skeletal muscle during middle and early older age, particularly for maintaining metabolic response to dietary macronutrients: carbohydrate (glucose), fat and protein during ageing. Whilst not the focus of the present paper, there is also growing evidence that certain vitamins and minerals such as vitamin C, carotenoids, magnesium and patterns of dietary intake are likely important for maintenance of skeletal muscle health, and could have a positive impact on protein synthesis in skeletal muscle^(1,12,37,126–131).

To date there are no dietary recommendations specifically for older people, or for maintaining skeletal muscle health during ageing, and such recommendations need to be developed⁽²⁾. We also do not know whether these recommendations would need to differ between men and women of older age. Until recommendations are made, research evidence suggests that public health practitioners should encourage individuals to follow healthy eating patterns that meet the current dietary guidelines, in particular reinforcing the importance of eating five fruit and vegetables daily, consuming adequate protein (0.8 g/kg), and limiting SFA and total fat intake.

Physical activity and exercise are clearly important for maintaining and building skeletal muscle at all ages. So both individual and population approaches for maintaining physical activity are required^(13,132). Older people should focus on resistance exercise or training, alongside activities that promote endurance and flexibility, since resistance training promotes rates of protein synthesis^(13,132). This is particularly important for those with sarcopenic obesity and type-2 diabetes and for maintaining blood glucose control in diabetes⁽¹³³⁾.

Clinicians and service providers, such as medical doctors, nurses and dietitians responsible for clients in middle and later life need to be particularly aware of the metabolic effects of skeletal muscle loss with ageing on the metabolism of macronutrients and energy expenditure. In their practice they should also be aware of these links to the prevention of obesity and their impact on the onset and treatment of type-2 diabetes.

Given the clear importance of maintaining SMM and quality with regard to the metabolism and utilisation of macronutrients and overall energy expenditure, as well as links to obesity and type-2 diabetes, more research is needed on how to preserve healthy skeletal muscle during ageing.

Financial Support

None.

Conflict of Interest

None.

Authorship

The authors had joint responsibility for all aspects of preparation of this paper.

References

1. Welch AA (2014) Nutritional influences on age-related skeletal muscle loss. *Proc Nutr Soc* **73**, 16–33.
2. Wolfe RR (2006) The underappreciated role of muscle in health and disease. *Am J Clin Nutr* **84**, 475–482.
3. Mitchell WK, Williams J, Atherton P *et al.* (2012) Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. *Front Physiol* **3**, 260.
4. Newman AB, Lee JS, Visser M *et al.* (2005) Weight change and the conservation of lean mass in old age: the health, aging and body composition study. *Am J Clin Nutr* **82**, 872–878; quiz 915–6.
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM *et al.* (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. *Age Ageing* **39**, 412–423.
6. Ethgen O, Beaudart C, Buckinx F *et al.* (2017) The future prevalence of sarcopenia in Europe: a claim for public health action. *Calcif Tissue Int* **100**, 229–234.
7. Cruz-Jentoft AJ, Bahat G, Bauer J *et al.* (2019) Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* **48**, 16–31.
8. Theodorakopoulos C, Jones J, Bannerman E *et al.* (2017) Effectiveness of nutritional and exercise interventions to improve body composition and muscle strength or function in sarcopenic obese older adults: a systematic review. *Nutr Res* **43**, 3–15.
9. Stenholm S, Harris TB, Rantanen T *et al.* (2008) Sarcopenic obesity: definition, cause and consequences. *Curr Opin Clin Nutr Metab Care* **11**, 693–700.
10. Johnson Stoklossa CA, Sharma AM, Forhan M *et al.* (2017) Prevalence of sarcopenic obesity in adults with class II/III obesity using different diagnostic criteria. *J Nutr Metab* **2017**, 7307618.
11. Batsis JA, Barre LK, Mackenzie TA *et al.* (2013) Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the national health and nutrition examination survey 1999–2004. *JAGS* **61**, 974–980.
12. Landi F, Camprubi-Robles M, Bear DE *et al.* (2018) Muscle loss: the new malnutrition challenge in clinical practice. *Clin Nutr* **38**, 2113–2120.
13. Deutz NEP, Ashurst I, Ballesteros MD *et al.* (2019) The underappreciated role of low muscle mass in the management of malnutrition. *J Am Med Dir Assoc* **20**, 22–27.
14. Argiles JM, Campos N, Lopez-Pedrosa JM *et al.* (2016) Skeletal muscle regulates metabolism via Interorgan cross-talk: roles in health and disease. *J Am Med Dir Assoc* **17**, 789–796.
15. Welch AA, Hayhoe RGP (2019) The relationship between dietary Fat and sarcopenia, skeletal muscle loss, osteoporosis and risk of fractures in aging. In *Nutritional Influences on Bone Health: 10th International Symposium*, pp. 211–227 [CM Weaver, H Bischoff-Ferrari, RM Daly *et al.*, editors]. Switzerland: Springer.
16. Abdelhamid A, Hooper L, Sivakaran R *et al.* (2019) The relationship between omega-3, omega-6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta-analysis of RCTs. *Calcif Tissue Int* **105**, 353–372.
17. Welch AA, Macgregor AJ, Minihihan AM *et al.* (2014) Dietary fat and fatty acid profile are associated with indices of skeletal muscle mass in women aged 18–79 years. *J Nutr* **144**, 327–334.

18. Cruz-Jentoft AJ, Landi F, Schneider SM *et al.* (2014) Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age Ageing* **43**, 748–759.
19. Wright NC, Looker AC, Saag KG *et al.* (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. *J Bone Miner Res* **29**, 2520–2526.
20. Scott D, de Courten B & Ebeling PR (2017) Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia's ageing population? *Med J Aust* **207**, 89.
21. Kalyani RR, Corriere M & Ferrucci L (2014) Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. *Lancet Diabetes Endocrinol* **2**, 819–829.
22. Rudrappa SS, Wilkinson DJ, Greenhaff PL *et al.* (2016) Human skeletal muscle disuse atrophy: effects on muscle protein synthesis, breakdown, and insulin resistance – a qualitative review. *Front Physiol* **7**, 361.
23. Cleasby ME, Jamieson PM & Atherton PJ (2016) Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. *J Endocrinol* **229**, R67–R81.
24. Janssen I, Shepard DS, Katzmarzyk PT *et al.* (2004) The healthcare costs of sarcopenia in the United States. *JAGS* **52**, 80–85.
25. Patel HP, White MC, Westbury L *et al.* (2015) Skeletal muscle morphology in sarcopenia defined using the EWGSOP criteria: findings from the Hertfordshire Sarcopenia Study (HSS). *BMC Geriatr* **15**, 171.
26. Buckinx F, Landi F, Cesari M *et al.* (2018) Pitfalls in the measurement of muscle mass: a need for a reference standard. *J Cachexia Sarcopenia Muscle* **9**, 269–278.
27. Heymsfield SB, Gallagher D, Mayer L *et al.* (2007) Scaling of human body composition to stature: new insights into body mass index. *Am J Clin Nutr* **86**, 82–91.
28. Heymsfield SB, Gonzalez MC, Lu J *et al.* (2015) Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. *Proc Nutr Soc* **74**, 1–12.
29. Heymsfield SB, Hwaung P, Ferreyro-Bravo F *et al.* (2019) Scaling of adult human bone and skeletal muscle mass to height in the US population. *Am J Hum Biol* **31**, e23252.
30. Heymsfield SB, Adamek M, Gonzalez MC *et al.* (2014) Assessing skeletal muscle mass: historical overview and state of the art. *J Cachexia Sarcopenia Muscle* **5**, 9–18.
31. Heymsfield SB, Wang Z, Baumgartner RN *et al.* (1997) Human body composition: advances in models and methods. *Annu Rev Nutr* **17**, 527–558.
32. Lam YY, Redman LM, Smith SR *et al.* (2014) Determinants of sedentary 24-h energy expenditure: equations for energy prescription and adjustment in a respiratory chamber. *Am J Clin Nutr* **99**, 834–842.
33. Prado CM & Heymsfield SB (2014) Lean tissue imaging: a new era for nutritional assessment and intervention. *JPEN: J Parenter Enteral Nutr* **38**, 940–953.
34. Heymsfield SB, Arteaga C, McManus C *et al.* (1983) Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. *Am J Clin Nutr* **37**, 478–494.
35. Dhurandhar NV, Schoeller D, Brown AW *et al.* (2015) Authors' response to LTE for 'energy balance measurement: when something is not better than nothing'. *Int J Obes (Lond)* **39**, 1175–1176.
36. Schuna JM Jr, Peterson CM, Thomas DM *et al.* (2015) Scaling of adult regional body mass and body composition as a whole to height: relevance to body shape and body mass index. *Am J Hum Biol* **27**, 372–379.
37. Welch AA, Skinner J & Hickson M (2017) Dietary magnesium may be protective for aging of bone and skeletal muscle in middle and younger older age men and women: cross-sectional findings from the UK Biobank cohort. *Nutrients* **9**, 1189.
38. Pearen MA, Eriksson NA, Fitzsimmons RL *et al.* (2012) The nuclear receptor, Nor-1, markedly increases type II oxidative muscle fibers and resistance to fatigue. *Mol Endocrinol* **26**, 372–384.
39. Edgerton VR, Smith J & Simpson D (1975) Muscle fibre type populations of human leg muscles. *Histochem J* **7**, 259–266.
40. Pette D & Staron RS (2001) Transitions of muscle fiber phenotypic profiles. *Histochem Cell Biol* **115**, 359–372.
41. Evans WJ & Lexell J (1995) Human aging, muscle mass, and fiber type composition. *J Gerontol Ser A: Biol Sci Med Sci* **50**(Special_Issue), 11–16.
42. Bua EA, McKiernan SH, Wanagat J *et al.* (2002) Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. *J Appl Physiol* **92**, 2617–2624.
43. Lexell J, Henriksson-Larsén K, Winblad B *et al.* (1983) Distribution of different fiber types in human skeletal muscles: effects of aging studied in whole muscle cross sections. *Muscle Nerve* **6**, 588–595.
44. Young A, Stokes M & Crowe M (1984) Size and strength of the quadriceps muscles of old and young women. *Eur J Clin Invest* **14**, 282–287.
45. Young A, Stokes M & Crowe M (1985) The size and strength of the quadriceps muscles of old and young men. *Clin Physiol* **5**, 145–154.
46. Wilkinson DJ, Piasecki M & Atherton PJ (2018) The age-related loss of skeletal muscle mass and function: measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. *Ageing Res Rev* **47**, 123–132.
47. Overend T, Cunningham D, Paterson D *et al.* (1992) Thigh composition in young and elderly men determined by computed tomography. *Clin Physiol* **12**, 629–640.
48. Søgaard D, Baranowski M, Larsen S *et al.* (2019) Muscle-saturated bioactive lipids are increased with aging and influenced by high-intensity interval training. *Int J Mol Sci* **20**, 1240.
49. Kayar S, Hoppeler H, Mermod L *et al.* (1988) Mitochondrial size and shape in equine skeletal muscle: a three-dimensional reconstruction study. *Anat Rec* **222**, 333–339.
50. Takahashi M & Hood DA (1996) Protein import into subsarcolemmal and intermyofibrillar skeletal muscle mitochondria differential import regulation in distinct subcellular regions. *J Biol Chem* **271**, 27285–27291.
51. Conley KE, Jubrias SA & Esselman PC (2000) Oxidative capacity and ageing in human muscle. *J Physiol* **526**(Pt 1), 203–210.
52. Herbst A, Pak JW, McKenzie D *et al.* (2007) Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers: evidence for a causal role in muscle fiber loss. *J Gerontol: Ser A* **62**, 235–245.
53. Wiley Christopher D, Velarde Michael C, Lecot P *et al.* (2016) Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. *Cell Metab* **23**, 303–314.
54. Jensen P (1966) Antimycin-insensitive oxidation of succinate and reduced nicotinamide-adenine dinucleotide in electron-transport particles I. pH dependency and hydrogen peroxide formation. *Biochim Biophys Acta (BBA), Enzymol Biol Oxid* **122**, 157–166.
55. Harman D (1972) The biologic clock: the mitochondria? *J Am Geriatr Soc* **20**, 145–147.

56. Murphy MP (2009) How mitochondria produce reactive oxygen species. *Biochem J* **417**, 1–13.
57. Baskin KK, Winders BR & Olson EN (2015) Muscle as a ‘mediator’ of systemic metabolism. *Cell Metab* **21**, 237–248.
58. Fan W, Atkins AR, Yu RT *et al.* (2013) Road to exercise mimetics: targeting nuclear receptors in skeletal muscle. *J Mol Endocrinol* **51**, T87–T100.
59. Muoio DM, Way JM, Tanner CJ *et al.* (2002) Peroxisome proliferator-activated receptor- α regulates fatty acid utilization in primary human skeletal muscle cells. *Diabetes* **51**, 901–909.
60. Schutz Y (2011) Protein turnover, ureagenesis and gluconeogenesis. *Int J Vitam Nutr Res* **81**, 101–107.
61. Wolfe RR, Miller SL & Miller KB (2008) Optimal protein intake in the elderly. *Clin Nutr* **27**, 675–684.
62. Waterlow JC (2006) *Protein Turnover*. Wallingford, UK, Cambridge, MA: CABI Pub.; x, 301 p.
63. Kim IY, Schutzler S, Schrader AM *et al.* (2018) Protein intake distribution pattern does not affect anabolic response, lean body mass, muscle strength or function over 8 weeks in older adults: a randomized-controlled trial. *Clin Nutr* **37**, 488–493.
64. Deutz NE, Bauer JM, Barazzoni R *et al.* (2014) Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN expert group. *Clin Nutr* **33**, 929–936.
65. Aversa Z, Zhang X, Fielding RA *et al.* (2019) The clinical impact and biological mechanisms of skeletal muscle aging. *Bone* **127**, 26–36.
66. Bogardus C, Taskinen MR, Zawadzki J *et al.* (1986) Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy. *Diabetes* **35**, 1–5.
67. Geisler C, Braun W, Pourhassan M *et al.* (2016) Age-dependent changes in resting energy expenditure (REE): insights from detailed body composition analysis in normal and overweight healthy Caucasians. *Nutrients* **8**, 322.
68. Muller MJ, Bosy-Westphal A, Kutzner D *et al.* (2003) Metabolically active components of fat free mass (FFM) and resting energy expenditure (REE) in humans. *Forum Nutr* **56**, 301–303.
69. Muller MJ, Bosy-Westphal A, Kutzner D *et al.* (2002) Metabolically active components of fat-free mass and resting energy expenditure in humans: recent lessons from imaging technologies. *Obes Rev* **3**, 113–122.
70. Lewis WH (1934) Changes with age in the basal metabolic rate in adult men. *Am Physiol Soc* **121**, 502–516.
71. Ravussin E, Lillioja S, Anderson TE *et al.* (1986) Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. *J Clin Invest* **78**, 1568–1578.
72. Fukagawa NK, Bandini LG & Young JB (1990) Effect of age on body composition and resting metabolic rate. *Am J Physiol* **259**, E233–E238.
73. Zurio F, Larson K, Bogardus C *et al.* (1990) Skeletal muscle metabolism is a major determinant of resting energy expenditure. *J Clin Invest* **86**, 1423–1427.
74. Weinsier RL, Schutz Y & Bracco D (1992) Reexamination of the relationship of resting metabolic rate to fat-free mass and to the metabolically active components of fat-free mass in humans. *Am J Clin Nutr* **55**, 790–794.
75. Barringer ND, Pasiakos SM, McClung HL *et al.* (2018) Prediction equation for estimating total daily energy requirements of special operations personnel. *J Int Soc Sports Nutr* **15**, 15.
76. Hopkins M, Finlayson G, Duarte C *et al.* (2019) Biological and psychological mediators of the relationships between fat mass, fat-free mass and energy intake. *Int J Obes (Lond)* **43**, 233–242.
77. Sergi G, Coin A, Bussolotto M *et al.* (2002) Influence of fat-free mass and functional status on resting energy expenditure in underweight elders. *J Gerontol Ser A, Biol Sci Med Sci* **57**, M302–M307.
78. Kim S, Welsh DA, Ravussin E *et al.* (2014) An elevation of resting metabolic rate with declining health in nonagenarians may be associated with decreased muscle mass and function in women and men, respectively. *J Gerontol Ser A, Biol Sci Med Sci* **69**, 650–656.
79. Soysal P, Ates Bulut E, Yavuz I *et al.* (2019) Decreased basal metabolic rate can be an objective marker for sarcopenia and frailty in older males. *J Am Med Dir Assoc* **20**, 58–63.
80. Wade AJ, Marbut MM & Round JM (1990) Muscle fibre type and aetiology of obesity. *Lancet* **335**, 805–808.
81. Tanner CJ, Barakat HA, Dohm GL *et al.* (2002) Muscle fiber type is associated with obesity and weight loss. *Am J Physiol Endocrinol Metab* **282**, E1191–E1196.
82. Phielix E & Mensink M (2008) Type 2 diabetes mellitus and skeletal muscle metabolic function. *Physiol Behav* **94**, 252–258.
83. Szendroedi J, Phielix E & Roden M (2011) The role of mitochondria in insulin resistance and type 2 diabetes mellitus. *Nat Rev Endocrinol* **8**, 92–103.
84. van de Weijer T, Sparks LM, Phielix E *et al.* (2013) Relationships between mitochondrial function and metabolic flexibility in type 2 diabetes mellitus. *PLoS ONE* **8**, e51648.
85. Goodpaster BH, Park SW, Harris TB *et al.* (2006) The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. *J Gerontol Ser A, Biol Sci Med Sci* **61**, 1059–1064.
86. Fabbri E, Chia CW, Spencer RG *et al.* (2017) Insulin resistance is associated with reduced mitochondrial oxidative capacity measured by ³¹P-magnetic resonance spectroscopy in participants without diabetes from the Baltimore longitudinal study of aging. *Diabetes* **66**, 170–176.
87. Phielix E, Szendroedi J & Roden M (2011) Mitochondrial function and insulin resistance during aging – A mini-review. *Gerontology* **57**, 387–396.
88. Affourtit C (2016) Mitochondrial involvement in skeletal muscle insulin resistance: a case of imbalanced bioenergetics. *Biochim Biophys Acta* **1857**, 1678–1693.
89. Barsalani R, Brochu M & Dionne IJ (2013) Is there a skeletal muscle mass threshold associated with the deterioration of insulin sensitivity in sedentary lean to obese postmenopausal women? *Diabetes Res Clin Pract* **102**, 123–128.
90. Park SW, Goodpaster BH, Strotmeyer ES *et al.* (2006) Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. *Diabetes* **55**, 1813–1818.
91. Leenders M, Verdijk LB, van der Hoeven L *et al.* (2013) Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. *J Am Med Dir Assoc* **14**, 585–592.
92. Kim CH, Kim HK, Kim EH *et al.* (2014) Association between changes in body composition and risk of developing type 2 diabetes in Koreans. *Diabet Med* **31**, 1393–1398.
93. Moon SS (2014) Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2010. *Endocr J* **61**, 61–70.

94. Jang HC (2016) Sarcopenia, frailty, and diabetes in older adults. *Diabetes Metab J* **40**, 182–189.
95. Sugimoto K, Tabara Y, Ikegami H *et al.* (2019) Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: the multicenter study for clarifying evidence for sarcopenia in patients with diabetes mellitus. *J Diabetes Investig* [Epublication ahead of print version].
96. Lee CG, Boyko EJ, Strotmeyer ES *et al.* (2011) Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. *J Am Geriatr Soc* **59**, 1217–1224.
97. Wang T, Feng X, Zhou J *et al.* (2016) Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. *Sci Rep* **6**, 38937.
98. Koo BK, Roh E, Yang YS *et al.* (2016) Difference between old and young adults in contribution of beta-cell function and sarcopenia in developing diabetes mellitus. *J Diabetes Investig* **7**, 233–240.
99. Cuthbertson DJ, Bell JA, Ng SY *et al.* (2016) Dynapenic obesity and the risk of incident type 2 diabetes: the English longitudinal study of ageing. *Diabet Med* **33**, 1052–1059.
100. Son JW, Lee SS, Kim SR *et al.* (2017) Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. *Diabetologia* **60**, 865–872.
101. Kim HK, Lee MJ, Kim EH *et al.* (2019) Longitudinal changes of body composition phenotypes and their association with incident type 2 diabetes mellitus during a 5-year follow-up in Koreans. *Diabetes Metab J* [Epublication ahead of print version].
102. Larsen BA, Wassel CL, Kritchevsky SB *et al.* (2016) Association of muscle mass, area, and strength with incident diabetes in older adults: the health ABC study. *J Clin Endocrinol Metab* **101**, 1847–1855.
103. Park SW, Goodpaster BH, Strotmeyer ES *et al.* (2007) Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. *Diabetes Care* **30**, 1507–1512.
104. Lee N & Choi CJ (2019) Smoking and diabetes as predictive factors of accelerated loss of muscle mass in middle-aged and older women: a six-year retrospective cohort study. *J Womens Health (Larchmt)* [Epublication ahead of print version].
105. Welch AA, Macgregor AJ, Skinner J *et al.* (2012) A higher alkaline dietary load is associated with greater indexes of skeletal muscle mass in women. *Osteoporos Int* **24**, 1899–1908.
106. Hayhoe RPG, Abdelhamid A, Luben RN *et al.* (2019) Dietary acid-base load and its association with risk of osteoporotic fractures and low skeletal muscle mass. *Eur J Clin Nutr* (In the Press).
107. Bouchi R, Fukuda T, Takeuchi T *et al.* (2017) Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. *Calcif Tissue Int* **101**, 1–8.
108. Spriet LL (2002) Regulation of skeletal muscle fat oxidation during exercise in humans. *Med Sci Sports Exerc* **34**, 1477–1484.
109. Frayn KN (2010) Fat as a fuel: emerging understanding of the adipose tissue-skeletal muscle axis. *Acta Physiol (Oxf)* **199**, 509–518.
110. Kob R, Fellner C, Bertsch T *et al.* (2015) Gender-specific differences in the development of sarcopenia in the rodent model of the ageing high-fat rat. *J Cachexia Sarcopenia Muscle* **6**, 181–191.
111. Linseisen J, Welch AA, Ocke M *et al.* (2009) Dietary fat intake in the European prospective investigation into cancer and nutrition: results from the 24-h dietary recalls. *Eur J Clin Nutr* **63**, Suppl. 4, S61–S80.
112. Holloway GP, Luiken JJ, Glatz JF *et al.* (2008) Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. *Acta Physiol (Oxf)* **194**, 293–309.
113. Andersson A, Nalsen C, Tengblad S *et al.* (2002) Fatty acid composition of skeletal muscle reflects dietary fat composition in humans. *Am J Clin Nutr* **76**, 1222–1229.
114. Andersson A, Sjodin A, Hedman A *et al.* (2000) Fatty acid profile of skeletal muscle phospholipids in trained and untrained young men. *Am J Physiol Metab* **279**, E744–E751.
115. DeLany JP, Windhauser MM, Champagne CM *et al.* (2000) Differential oxidation of individual dietary fatty acids in humans. *Am J Clin Nutr* **72**, 905–911.
116. Lipina C & Hundal HS (2017) Lipid modulation of skeletal muscle mass and function. *J Cachexia Sarcopenia Muscle* **8**, 190–201.
117. Public Health England (2019) The Scientific Advisory Committee on Nutrition (SACN) report on saturated fats and health.
118. Calder PC, Albers R, Antoine JM *et al.* (2009) Inflammatory disease processes and interactions with nutrition. *Br J Nutr* **101**, Suppl. 1, S1–45.
119. Da Boit M, Sibson R, Sivasubramaniam S *et al.* (2017) Sex differences in the effect of fish-oil supplementation on the adaptive response to resistance exercise training in older people: a randomized controlled trial. *Am J Clin Nutr* **105**, 151–158.
120. Tachtsis B, Camera D & Lacham-Kaplan O (2018) Potential roles of n-3 PUFAs during skeletal muscle growth and regeneration. *Nutrients* **10**, 309.
121. Ferrucci L, Corsi A, Lauretani F *et al.* (2005) The origins of age-related proinflammatory state. *Blood* **105**, 2294–2299.
122. Maggio M, Guralnik JM, Longo DL *et al.* (2006) Interleukin-6 in aging and chronic disease: a magnificent pathway. *J Gerontol Ser A, Biol Sci Med Sci* **61**, 575–584.
123. Collino M, Mastrocola R, Nigro D *et al.* (2014) Variability in myosteatosis and insulin resistance induced by high-fat diet in mouse skeletal muscles. *Biomed Res Int* **2014**, 569623.
124. Kosmidou I, Vassilakopoulos T, Xagorari A *et al.* (2002) Production of interleukin-6 by skeletal myotubes: role of reactive oxygen species. *Am J Respir Cell Mol Biol* **26**, 587–593.
125. Addison O, Drummond MJ, LaStayo PC *et al.* (2014) Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity. *J Nutr Health Aging* **18**, 532–538.
126. Robinson SM, Reginster JY, Rizzoli R *et al.* (2017) Does nutrition play a role in the prevention and management of sarcopenia? *Clin Nutr* **37**, 1121–1132.
127. Hayhoe RPG, Lentjes MAH, Mulligan AA *et al.* (2018) Cross-sectional associations of dietary and circulating magnesium with skeletal muscle mass in the EPIC-Norfolk cohort. *Clin Nutr* **38**, 317–323.
128. Kelaiditi E, Jennings A, Steves CJ *et al.* (2016) Measurements of skeletal muscle mass and power are positively related to a Mediterranean dietary pattern in women. *Osteoporos Int* **27**, 3251–3260.
129. Welch AA, Kelaiditi E, Jennings A *et al.* (2016) Dietary magnesium is positively associated with skeletal muscle power and indices of muscle mass and may attenuate the association between circulating C-reactive protein and muscle mass in women. *J Bone Miner Res* **31**, 317–325.
130. Granic A, Sayer AA & Robinson SM (2019) Dietary patterns, skeletal muscle health, and sarcopenia in older adults. *Nutrients* **11**, 745.



131. van Dronkelaar C, van Velzen A, Abdelrazek M *et al.* (2018) Minerals and sarcopenia; the role of calcium, iron, magnesium, phosphorus, potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: a systematic review. *J Am Med Dir Assoc* **19**, 6–11, e3.
132. Piercy KL, Troiano RP, Ballard RM *et al.* (2018) The physical activity guidelines for Americans. *JAMA* **320**, 2020–2028.
133. Mori H, Kuroda A & Matsuhisa M (2019) Clinical impact of sarcopenia and dynapenia on diabetes. *Diabetol Int* **10**, 183–187.